07:00 , Apr 13, 2015 |  BC Week In Review  |  Clinical News

Cenderitide: Completed Phase II enrollment

Capricor completed enrollment of 14 patients in an open-label, dose-escalation, U.S. Phase II trial evaluating 0.5, 1, 2 and 3 ng/kg/min cenderitide given as a 48-hour continuous, subcutaneous infusion via Insulet’s OmniPod drug delivery system...
07:00 , Mar 9, 2015 |  BC Week In Review  |  Clinical News

Cenderitide: Phase II started

Capricor began an open-label, dose-escalation, U.S. Phase II trial to evaluate 0.5, 1, 2 and 3 ng/kg/min cenderitide given as a 48-hour continuous infusion via the Insulet Drug Delivery System for up to 8 days...
08:00 , Nov 24, 2014 |  BC Week In Review  |  Company News

Medtronic, Capricor Therapeutics deal

Capricor purchased Medtronic’s patent related to the formulation and pump delivery of natriuretic peptides to treat post-acute heart failure. Medtronic will receive a $100,000 upfront payment and is eligible for $7 million in milestones. Medtronic...
07:00 , Jul 15, 2013 |  BC Week In Review  |  Company News

Capricor, Nile Therapeutics deal

Capricor will reverse-merge with Nile in a stock deal. Nile will issue Capricor stockholders shares of Nile stock so that Capricor will own about 90% of the combined company, which will be called Capricor...
08:00 , Jan 2, 2012 |  BC Week In Review  |  Clinical News

Cenderitide: Phase I data

Top-line data from a placebo-controlled, U.S. Phase I trial in 58 patients with ADHF showed that subcutaneous infusions of cenderitide met the primary endpoint by achieving undisclosed target PK levels. Additionally, 24-hour subcutaneous infusions of...
07:00 , Oct 24, 2011 |  BC Week In Review  |  Clinical News

Cenderitide: Phase I ongoing

Nile completed dosing in a placebo-controlled, U.S. Phase I trial in 58 patients evaluating subcutaneous cenderitide. Patients received 2 bolus injections of cenderitide, or 2 fixed dose levels or a weight-based dose of cenderitide as...
07:00 , May 9, 2011 |  BC Week In Review  |  Clinical News

Cenderitide: Phase I started

Nile began a single-blind, placebo-controlled, U.S. Phase I trial in about 48 patients to evaluate subcutaneous cenderitide given as a bolus or an infusion delivered via subcutaneous pump technology from Medtronic Inc. (NYSE:MDT, Minneapolis,...
07:00 , Apr 4, 2011 |  BC Week In Review  |  Clinical News

Cenderitide regulatory update

FDA granted Fast Track designation for Nile's cenderitide to treat patients with acute decompensated heart failure (ADHF) in the post-acute period. Nile plans to start a Phase II trial of the selective natriuretic peptide...
08:00 , Mar 7, 2011 |  BC Week In Review  |  Company News

Nile Therapeutics, Medtronic deal

Medtronic will fund Nile's Phase I trial to evaluate cenderitide (formerly CD-NP) delivered through Medtronic's diabetes pump technology to treat heart failure. Nile expects to start the trial next quarter, with data expected...
08:00 , Nov 22, 2010 |  BC Week In Review  |  Clinical News

CD-NP: Phase II data

A single-blind, placebo-controlled Phase II trial in 77 patients with ADHF and mild to moderate renal insufficiency showed that 1.25, 2.5 and 3.75 ng/kg/min infusions of CD-NP administered for up to 72 hours were well...